Header links
Intranet
Donate now
image/svg+xml Map
Contact us

POETYK PsA-2 (055) - Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del deucravacitinib en pacientes con artritis psoriásica activa (APs) naïve a medicamentos biológicos antirreumáticos modificadores de la enfermedad o que previamente han sido tratados con un inhibidor del TNFa

Contact
  • Protocol code: IM011-055
  • EudraCT code: 2020-005099-36
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Marsal Barril, Sara
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo multicéntrico Fase III, aleatorizado, doble-ciego, controlado frente a placebo, para evaluar la eficacia de ciclosilicato de sodio y zirconio en la progresión de la enfermedad renal crónica (ERC) en pacientes con ERC e hiperpotasemia o con riesgo de hiperpotasemia

Contact
  • Protocol code: D9488C00001
  • EudraCT code: 2021-001911-96
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo aleatorizado, doble ciego (dentro de los grupos de dosis), controlado con placebo y con grupos paralelos para investigar los efectos de diferentes dosis de BI 685509 administradas por vía oral durante 20 semanas sobre la reducción del UACR en pacientes con nefropatía no diabética.

Contact
  • Protocol code: 1366-0022
  • EudraCT code: 2020-002930-33
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la seguridad y eficacia a largo plazo de lanifibranor en pacientes adultos con esteatohepatitis no alcohólica (EHNA) sin cirrosis y estadio de fibrosis hepática grado 2 (F2)/grado 3 (F3)

Contact
  • Protocol code: 337HNAS20011
  • EudraCT code: 2020-004986-38
  • Pathology: Malalties del sistema digestiu
  • Principal investigator:  Pericàs Pulido, Juan Manuel
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

DTG // 3TC frente a BIC // FTC // TAF como terapia de mantenimiento en personas que viven con VIH: ensayo clínico abierto y aleatorizado

Contact
  • Protocol code: GESIDA11720
  • EudraCT code: 2020-003686-18
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Curran Fàbregas, Adria
  • Research group:  Malalties infeccioses
  • Service: Infeccioses
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo multicéntrico, aleatorizado, de grupos paralelos, controlado con placebo (doble ciego) y con tratamiento activo (abierto) para comparar la eficacia y seguridad de lonapegsomatropina una vez a la semana frente a placebo una vez a la semana y un producto de somatropina diaria en adultos con deficiencia de hormona del crecimiento

Contact
  • Protocol code: TCH-306
  • EudraCT code: 2020-000929-42
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Biagetti Biagetti, Betina
  • Research group:  Diabetis i metabolisme
  • Service: Endocrinologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio aleatorizado, con enmascaramiento doble y comparativo con un placebo, en el que se evalúa galcanezumab en pacientes adolescentes de entre 12 y 17 años con migraña crónica - Estudio REBUILD-2

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase III, multicéntrico, doble ciego y aleatorizado para evaluar la eficacia y seguridad de OPT-302 intravítreo en combinación con aflibercept, en comparación con aflibercept en monoterapia, en participantes con degeneración macular asociada a la edad (DMAE)

Contact
  • Protocol code: OPT-302-1005
  • EudraCT code: 2020-004694-46
  • Pathology: Malalties de l’ull i dels seus annexos
  • Principal investigator:  García Arumí, José
  • Research group:  Oftalmologia
  • Service: Oftalmologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de MK-3655 en personas con esteatohepatitis no alcohólica precirrótica.

Contact
  • Protocol code: MK-3655-001
  • EudraCT code: 2019-003048-63
  • Pathology: Malalties del sistema digestiu
  • Principal investigator:  Vargas Blasco, Victor Manuel
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea(Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del mpolvo en pacientes con rinitis//rinoconjuntivitis alérgica

Contact
  • Protocol code: PRO-RCT-ACAROS-2018-01
  • EudraCT code: 2018-003427-11
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Cardona Dahl, Victòria
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to